accord
nation
hospit
ambulatori
medic
survey
patient
sought
treatment
emerg
depart
ed
febril
time
present
second
abdomin
pain
cramp
fever
second
common
chief
complaint
patient
came
ed
year
common
chief
complaint
patient
younger
year
presenc
fever
prompt
question
whether
antimicrobi
administ
empir
survey
data
also
indic
antimicrobi
prescrib
drug
categori
second
analges
ed
around
unit
state
visit
involv
administr
least
antimicrobi
antimicrobi
order
ed
everi
day
sometim
indic
straightforward
choic
simpl
time
decis
author
conflict
interest
disclos
difficult
patient
present
fever
trigger
consider
administr
antimicrobi
frequent
decis
initi
empir
treatment
need
made
definit
diagnosi
known
case
organ
approach
help
determin
caus
fever
subsequ
treat
appropri
depend
multipl
factor
ideal
patient
enter
ed
clear
histori
classic
physic
examin
find
result
diagnost
test
mark
obviou
path
howev
thorough
histori
physic
examin
hinder
uncontrol
element
alter
mental
statu
result
diagnost
test
equivoc
even
fals
therefor
empir
antimicrobi
therapi
becom
cornerston
treatment
emerg
physician
balanc
respons
stewardship
health
resourc
need
provid
effect
treatment
promptli
goal
review
provid
systemsbas
approach
prescrib
antimicrobi
patient
present
ed
fever
understand
risk
associ
overutil
seek
provid
understand
key
consider
need
ensur
decis
made
well
appropri
treatment
begin
promptli
uncommonli
physician
decid
antimicrobi
need
even
though
definit
infecti
diagnosi
yet
establish
case
empir
therapi
initi
target
potenti
sourc
infect
deem
like
seriou
spectrum
coverag
guid
preliminari
impress
probabl
infecti
site
base
histori
physic
examin
relev
demograph
inform
medic
histori
laboratori
data
result
diagnost
imag
therefor
good
understand
surround
epidemiolog
particularli
import
mani
hospit
routin
gather
cultur
result
sensit
data
analysi
construct
hospit
antibiogram
provid
antibiot
recommend
link
specif
clinic
scenario
inform
particularli
use
emerg
servic
provid
other
see
patient
earli
cours
ill
case
definit
differenti
need
administ
antibiot
earli
empir
particularli
press
set
sever
infecti
ill
includ
sepsi
pneumonia
mening
although
controversi
remain
well
establish
antibiot
need
administ
empir
earli
select
case
base
clinic
judgment
particularli
wellknown
illustr
found
work
emanuel
river
other
strategi
known
earli
goaldirect
therapi
show
signific
posit
impact
outcom
among
patient
septic
shock
surviv
sepsi
guidelin
emphas
administr
effect
antimicrobi
within
first
hour
recognit
sever
sepsi
septic
shock
assess
vulner
patient
decis
prescrib
antimicrobi
inform
thorough
assess
variabl
relat
host
patient
unabl
toler
certain
treatment
hypersensit
reaction
patient
might
report
histori
allergi
past
even
though
true
allergi
exist
import
investig
whether
histori
intoler
base
true
allergi
less
seriou
problem
exampl
patient
might
experienc
gastrointestin
distress
take
macrolid
past
therefor
refus
take
despit
true
hypersensit
reaction
antibiot
patient
acut
chronic
organ
dysfunct
might
requir
antibiot
strategi
deviat
routin
standard
approach
particularli
common
exampl
renal
dysfunct
renal
failur
whether
acut
chronic
affect
elimin
antibiot
consid
establish
appropri
dose
time
interv
antibiot
clear
kidney
addit
antibiot
directli
caus
renal
hepat
toxic
avoid
patient
underli
diseas
immunocompromis
patient
rais
particularli
import
issu
patient
expos
common
pathogen
infect
otherwis
healthi
individu
time
particularli
suscept
atyp
infect
includ
fungal
infect
infect
resist
particularli
virul
organ
eg
pseudomona
immunocompet
patient
less
vulner
understand
host
respons
infect
signific
impact
treatment
choic
time
immunocompromis
host
present
atyp
may
mount
fever
may
show
classic
sign
sever
late
diseas
cours
situat
could
lead
delay
administr
antibiot
failur
manag
patient
aggress
initi
present
drug
interact
heighten
patient
vulner
certain
complic
exampl
patient
warfarin
anticoagul
therapi
may
need
avoid
fluoroquinolon
prevent
coagulopathi
quinolon
must
use
use
inadvert
essenti
check
intern
normal
ratio
monitor
coagul
statu
similarli
patient
receiv
metronidazol
advis
avoid
alcohol
associ
disulfiramlik
reaction
nausea
vomit
flush
skin
tachycardia
although
comorbid
medic
condit
per
se
socioeconom
variabl
render
patient
vulner
infect
less
abl
access
appropri
treatment
financi
barrier
signific
cost
medicin
need
consid
relat
patient
capac
compli
recommend
patient
discharg
recommend
outpati
followup
cost
antimicrobi
dose
schedul
becom
signific
driver
adher
gener
brand
found
formulari
larg
pharmaci
typic
afford
medicin
requir
frequent
dose
difficult
take
correctli
result
complianc
therapi
might
suboptim
histori
physic
examin
coupl
laboratori
test
imag
help
identifi
site
possibl
infect
patient
present
fever
ed
site
infect
difficult
penetr
antibiot
given
anatomi
blood
flow
therefor
limit
concentr
antibiot
reach
organ
area
suffer
significantli
lower
concentr
antibiot
includ
cerebrospin
fluid
csf
prostat
pancrea
skin
soft
tissu
patient
poorli
control
diabet
peripher
vascular
diseas
vitreou
humor
eye
fever
use
antimicrobi
ed
pathogen
like
multipl
antibiot
administ
consid
first
give
antibiot
like
attack
offend
organ
guidanc
systemsbas
review
follow
exampl
diabet
nursinghom
patient
risk
pseudomona
aeruginosa
like
caus
pneumonia
remain
gramposit
coccu
therefor
streptococcu
pneumonia
target
first
need
also
cover
p
aeruginosa
address
time
sequenc
administr
choos
empir
antimicrobi
import
consid
pharmacokinet
practic
featur
option
consider
exampl
combin
pipericillintazobactam
vancomycin
commonli
use
provid
broadspectrum
coverag
prescrib
physician
judg
methicillinresist
staphylococcu
aureu
mrsa
p
aeruginosa
need
cover
empir
typic
pipericillintazobactam
administ
rapidli
vancomycin
may
prudent
give
pipericillintazobactam
first
intraven
antimicrobi
might
prefer
oral
option
need
achiev
effect
therapeut
index
rapidli
judg
particularli
press
though
somewhat
controversi
common
strategi
administ
singl
dose
intraven
antibiot
follow
oral
agent
provid
similar
coverag
requir
time
reach
effect
therapeut
level
exampl
patient
given
dose
intraven
ampicillinsulbactam
follow
oral
amoxicillinclavulan
although
research
support
approach
limit
arguabl
combin
desir
effect
earli
arriv
effect
therapeut
level
practic
prefer
outpati
manag
appropri
select
patient
bactericid
drug
kill
bacteria
wherea
bacteriostat
drug
inhibit
cell
growth
drug
bactericid
need
reach
near
concentr
bacteriostat
drug
requir
reach
kill
organ
bactericid
drug
often
kill
time
mean
inhibitori
concentr
mic
wherea
bacteriostat
drug
may
kill
reach
concentr
time
mic
therefor
consid
infect
locat
poor
blood
flow
prostat
treat
patient
signific
microvascular
diseas
eg
person
poorli
control
diabet
bactericid
drug
might
benefici
reach
effect
concentr
host
infect
tissu
without
reach
toxic
level
organ
system
despit
differ
efficaci
bacteriostat
drug
play
import
role
treat
infect
bacteriostat
agent
contain
growth
organ
allow
host
immun
system
fight
infect
specif
featur
patient
must
consid
predict
whether
host
abl
mount
suffici
respons
fight
infect
remain
bactericid
agent
prefer
patient
immunocompromis
neutropen
endovascular
infect
endocard
mening
cerebr
abscess
osteomyel
bacteriostat
antibiot
particularli
benefici
diseas
process
caus
organ
divid
rapidli
produc
toxin
target
antibiot
exampl
toxic
shock
syndrom
system
manifest
group
streptococci
ga
infect
secondari
toxin
produc
ga
clindamycin
though
bacteriostat
drug
choic
situat
mechan
action
decreas
toxin
product
therebi
lessen
system
symptom
tabl
data
center
diseas
control
prevent
cdc
demonstr
resist
persist
grow
public
health
concern
unless
signific
action
taken
alter
way
antibiot
steward
physician
organ
resist
newest
strongest
antibiot
continu
emerg
novemb
nation
institut
health
nih
pew
health
group
publish
studi
highlight
absolut
necess
improv
prescrib
habit
educ
patient
mani
american
understand
import
antibiot
resist
know
full
cours
prescrib
antibiot
taken
even
alway
compli
recommend
patient
believ
organ
becom
resist
antibiot
commun
low
suspicion
organ
affect
famili
member
physician
role
patient
educ
take
respons
overprescrib
antibiot
utmost
import
prescrib
rate
antibiot
fallen
nationwid
sinc
although
state
progress
other
emerg
physician
frequent
feel
pressur
patient
prescrib
antibiot
number
antibiot
antimicrobi
develop
fallen
drastic
past
sever
decad
pharmaceut
compani
introduc
new
antimicrobi
agent
market
sinc
steadi
declin
product
new
antibiot
introduc
sinc
new
agent
develop
pew
health
group
identifi
sever
challeng
antibiot
innov
scientif
new
class
antibiot
novel
mechan
action
difficult
discov
econom
antibiot
produc
lower
revenu
pharmaceut
addit
achiev
approv
new
antibiot
us
food
drug
administr
fda
becom
challeng
investig
find
difficult
amass
suffici
number
studi
subject
regulatori
measur
tighter
requir
new
agent
must
show
improv
efficaci
decreas
advers
reaction
toxic
financi
burden
associ
resist
organ
increas
cdc
estim
year
resist
infect
account
billion
manag
cost
contribut
estim
million
addit
hospit
day
increas
number
organ
identifi
resist
strain
north
america
abroad
preval
drugresist
pathogen
cite
cdc
acinetobact
group
b
streptococci
klebsiella
pneumonia
mrsa
neisseria
meningitidi
shigella
pneumonia
vancomycinresist
enterococci
candida
human
immunodefici
viru
hiv
organ
caus
anthrax
gonorrhea
tuberculosi
typhoid
fever
influenza
malaria
therefor
time
increas
resist
efficaci
antibiot
deploy
creat
least
amount
induc
resist
within
host
deliv
precis
target
suscept
organ
affect
organ
system
mening
enceph
secondari
bacteri
infect
confer
signific
risk
morbid
mortal
earli
diagnosi
treatment
remain
essenti
avert
death
disabl
neurolog
sequela
typic
present
warrant
empir
treatment
includ
appropri
time
diagnost
studi
earli
antibiot
atyp
present
pose
diagnost
challeng
emphas
import
maintain
high
index
suspicion
condit
care
consid
time
sequenc
therapeut
effort
although
incident
case
bacteri
mening
enceph
rel
rare
consid
true
neurolog
emerg
mening
enceph
suspect
empir
administr
appropri
antibiot
serious
consid
earli
possibl
proulx
colleagu
demonstr
patient
receiv
antibiot
ed
significantli
less
like
die
patient
receiv
antibiot
arriv
inpati
servic
mortal
rate
respect
studi
shown
less
robust
effect
earli
antibiot
administr
typic
manifest
meningitisenceph
fever
headach
nuchal
rigid
alter
mental
statu
clinic
syndrom
fever
headach
prompt
consider
meningoenceph
although
symptom
nonspecif
appropri
evalu
includ
certain
diagnost
test
may
caus
signific
delay
definit
therapi
particular
appropri
time
comput
tomographi
ct
head
lumbar
punctur
blood
cultur
need
consid
relat
expect
clinic
benefit
compar
earlier
administr
antibiot
possibl
steroid
infecti
diseas
societi
america
idsa
guidelin
bacteri
mening
emphas
blood
cultur
obtain
lumbar
punctur
perform
promptli
administr
parenter
antibiot
steroid
determin
head
ct
scan
need
analysi
csf
allow
differenti
bacteri
viral
mening
posit
gram
stain
point
convincingli
toward
bacteri
sourc
wherea
neg
gram
stain
exclud
occult
bacteri
infect
csf
cell
count
chemistri
expect
demonstr
typic
pattern
correspond
either
viral
bacteri
sourc
nevertheless
result
sometim
equivoc
csf
cultur
also
use
requir
hour
provid
use
inform
candid
marker
csf
includ
lactat
procalcitonin
level
activ
investig
correl
bacteri
mening
evid
recommend
routin
use
lack
imperfect
predict
bacteri
mening
base
csf
analysi
emphas
point
empir
therapi
bacteri
infect
could
prudent
regardless
test
result
select
case
case
requir
prompt
treatment
bacteri
mening
typic
present
typic
atyp
present
along
object
test
result
rais
concern
atyp
featur
includ
equivoc
test
result
patient
addit
unreassur
find
eg
system
inflamm
hypotens
alter
mental
statu
common
approach
antibiot
administr
target
mening
infect
present
tabl
sinus
fever
common
present
symptom
associ
acut
maxillari
sinus
fever
present
whether
infect
caus
viru
commonli
rhinoviru
bacterium
commonli
pneumonia
h
influenza
therefor
presenc
fever
use
antimicrobi
ed
fever
use
guid
treatment
case
acut
rhiniti
sinus
viral
sourc
run
benign
cours
fact
coupl
grow
concern
bacteri
resist
led
cdc
advis
judici
use
antibiot
support
care
decongest
suffici
treat
viral
sinus
longer
durat
symptom
suggest
bacteri
sourc
cours
antibiot
might
advis
symptom
last
longer
day
patient
febril
sever
symptom
pain
purul
discharg
patient
experienc
resolut
symptom
upper
respiratori
infect
headach
facial
pain
purul
nasal
discharg
return
infect
commonli
caus
pneumonia
h
influenza
blactam
blactamas
inhibitor
indic
increas
resist
previou
decad
emphas
import
select
antibiot
effect
blactamaseproduc
organ
patient
allerg
penicillin
doxycyclin
prefer
fluoroquinolon
recommend
resist
macrolid
widespread
recommend
firstlin
therapi
empir
coverag
mrsa
recommend
adult
pharyng
frequent
viral
infect
adult
like
children
remain
suscept
group
bhemolyt
streptococci
gonococc
infect
less
common
nevertheless
import
caus
bacteri
pharyng
approxim
case
adult
pharyng
secondari
group
streptococci
group
risk
acut
rheumat
fever
centor
criteria
use
guid
diagnosi
treatment
acut
pharyng
histori
fever
absenc
cough
tonsillar
exud
tender
anterior
cervic
lymphadenopathi
criteria
posit
patient
treat
empir
ga
patient
criteria
test
rapid
streptococc
antigen
test
result
posit
patient
treat
penicillin
patient
allerg
penicillin
macrolid
may
use
acut
bronchiti
acut
respiratori
ill
character
cough
without
sputum
product
last
week
upper
respiratori
infect
case
viral
origin
common
culprit
influenza
parainfluenza
respiratori
syncyti
viru
adenoviru
bacteria
implic
common
organ
bordetella
pertussi
mycoplasma
pneumonia
chlamydia
pneumonia
routin
empir
treatment
antimicrobi
recommend
acut
bronchiti
howev
patient
present
within
hour
symptom
onset
polymeras
chain
reaction
nasal
swab
confirm
influenza
b
neuraminidas
inhibitor
ie
oseltamivir
zanamivir
may
decreas
sever
durat
symptom
therefor
use
select
popul
cdc
recommend
initi
antivir
treatment
soon
possibl
patient
influenza
suspect
confirm
hospit
sever
complic
underli
progress
ill
risk
influenza
complic
follow
group
consid
high
risk
complic
extrem
age
year
year
signific
chronic
pulmonari
diseas
neurolog
diseas
diabet
immunocompromis
state
women
pregnant
postpartum
period
within
week
deliveri
younger
year
longterm
aspirin
therapi
american
indiansalaska
nativ
morbidli
obes
bodi
mass
index
kgm
resid
chronic
care
facil
cdc
longer
recommend
treatment
influenza
amantadin
strain
test
sinc
found
resist
patient
appar
bronchiti
experi
episod
worsen
ill
persist
highpitch
cough
diagnosi
b
pertussi
entertain
patient
characterist
either
fever
use
antimicrobi
ed
receiv
pertussi
vaccin
receiv
year
previous
empir
treatment
macrolid
consid
trimethoprimsulfamethoxazol
may
administ
patient
allerg
macrolid
pneumonia
eighth
lead
caus
death
unit
state
given
epidemiolog
signific
research
polici
prioriti
focus
earli
recognit
treatment
joint
commiss
accredit
healthcar
organ
center
medicar
medicaid
servic
identifi
earli
antibiot
administr
pneumonia
core
perform
measur
relev
literatur
suggest
real
limit
benefit
earli
antibiot
administr
communityacquir
pneumonia
cap
benefit
earlier
treatment
patient
nosocomi
infect
health
careassoci
pneumonia
ventilatorassoci
pneumonia
signific
appar
patient
cap
often
present
typic
featur
includ
fever
cough
infiltr
chest
film
ill
particularli
sever
patient
immunocompromis
present
domin
nonspecif
featur
alter
mental
statu
atyp
find
hypothermia
absenc
fever
cap
bacteri
viral
origin
commonli
implic
bacteria
pneumonia
mycoplasma
pneumonia
c
pneumonia
h
influenza
legionella
pneumophila
anaerob
aspir
gramneg
bacilli
viral
caus
includ
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
human
metapneumoviru
hantaviru
coronaviru
varicella
rubeola
essenti
approach
suspect
pneumonia
requir
estim
sever
includ
determin
whether
inpati
outpati
treatment
need
literatur
provid
sever
predict
rule
may
help
pneumonia
sever
index
psi
port
score
one
commonli
use
tool
psi
includ
marker
could
therefor
prove
cumbersom
applic
mani
clinic
set
anoth
commonli
use
predict
rule
method
promot
british
thorac
societi
tool
less
complex
psi
applic
feasibl
clinic
set
key
element
given
point
describ
c
confus
defin
disorient
place
time
person
anoth
find
caus
concern
examin
mental
statu
u
uremia
blood
urea
nitrogen
level
higher
mmoll
mgdl
r
respiratori
rate
breathsmin
b
low
blood
pressur
systol
mm
hg
diastol
mm
hg
age
year
older
simplifi
recommend
patient
total
score
treat
outpati
basi
score
warrant
admiss
inpati
ward
score
consid
care
intens
care
unit
score
system
suffici
replac
clinic
judgment
suffici
judgment
might
allow
either
tool
use
appropri
select
situat
addit
like
pathogen
identifi
appropri
spectrum
activ
antibiot
coverag
determin
toward
end
american
thorac
societi
at
idsa
jointli
publish
guidelin
box
at
idsa
divid
hospitalacquir
pneumonia
categori
health
careassoci
pneumonia
hcap
ventilatorassoci
pneumonia
vap
hcap
nosocomi
infect
acquir
acut
care
hospit
chronic
care
facil
vap
occur
acut
critic
ill
patient
chronic
respiratori
failur
requir
mechan
ventil
common
multidrugresist
gramneg
bacteri
pathogen
caus
hospitalacquir
pneumonia
p
aeruginosa
pathogen
consid
k
pneumonia
enterobact
serratia
acinetobact
stenotrophomona
burkholderia
cepacia
mrsa
pneumonia
h
influenza
legionella
candida
aspergillu
influenza
parainfluenza
adenoviru
measl
respiratori
syncyti
viru
treatment
decis
base
patient
risk
profil
drugresist
organ
patient
highest
risk
chronic
care
facil
frequent
dialysi
center
hospit
day
previou
day
live
commun
high
preval
resist
famili
member
known
resist
organ
immunosuppress
tabl
discuss
earlier
treat
drugresist
organ
imper
understand
local
resist
pattern
awar
institut
recommend
base
inhous
epidemiolog
studi
antibiogram
importantli
consid
resist
pattern
document
specif
patient
medic
histori
public
health
implic
surround
tuberculosi
tb
clinician
maintain
high
index
suspicion
toward
patient
risk
diseas
cdc
delin
follow
highrisk
popul
immunocompromis
incarcer
intern
travel
immigr
countri
high
preval
tb
high
clinic
suspicion
activ
tb
patient
assess
ed
warrant
initi
appropri
precaut
treatment
preval
organ
resist
isoniazid
high
world
health
organ
recommend
administr
antimicrobi
patient
suspect
activ
tb
first
month
treatment
ethambutol
isoniazid
rifampin
pyrazinamid
establish
diagnosi
infect
endocard
particularli
challeng
earli
cours
ill
duke
criteria
use
guid
decis
begin
empir
therapi
ed
tabl
approach
recommend
initi
treatment
ed
case
meet
major
criteria
major
minor
criteria
minor
criteria
empir
therapi
typic
institut
unless
patient
becom
acut
ill
exhibit
sign
sepsi
treatment
initi
seriou
effort
identifi
infecti
sourc
undertaken
appropri
blood
cultur
essenti
effort
use
least
sampl
site
possibl
common
offend
organ
aureu
patient
nativ
valv
initi
treatment
ampicillinsulbactam
combin
gentamicin
recommend
case
patient
allerg
penicillin
treatment
vancomycin
combin
gentamicin
ciprofloxacin
consid
endocard
develop
intraven
drug
abus
infect
organ
usual
aureu
vancomycin
commonli
recommend
patient
popul
clinician
remain
alert
possibl
polymicrobi
infect
patient
patient
prosthet
valv
receiv
broader
coverag
administ
aggress
coverag
bartonella
speci
particular
ensur
common
recommend
ceftriaxon
gentamicin
without
doxycyclin
patient
activ
symptomat
clinic
condit
remain
stabl
admiss
workup
establish
diagnosi
definit
recommend
endocard
suspect
intralumin
intestin
flora
common
caus
intraabdomin
infect
surgic
infect
societi
idsa
jointli
issu
recommend
pertain
patient
abdomin
infect
abdomin
infect
suspect
sign
system
inflamm
hypoperfus
present
administr
antibiot
begin
empir
parallel
effort
definit
identifi
sourc
intraabdomin
sourc
infect
suspect
surgic
consult
necessari
plan
treatment
cours
common
microbi
caus
abdomin
infect
enter
gramneg
aerob
facult
bacilli
enter
gramposit
streptococci
antimicrobi
treatment
includ
coverag
organ
distal
small
bowel
appendix
colon
involv
oblig
anaerob
bacilli
also
cover
current
guidelin
suggest
routin
blood
cultur
tend
help
blood
cultur
like
help
patient
exhibit
sign
sepsi
immunocompromis
resist
organ
suspect
standard
recommend
empir
coverag
adult
patient
mild
moder
diseas
call
administr
cefoxitin
ertapenem
moxifloxacin
tigecyclin
ticarcillinclavulan
acid
ill
judg
sever
patient
vulner
judg
high
someon
advanc
age
immunocompromis
host
broader
coverag
typic
advis
decis
regard
treatment
nosocomi
infect
guid
cultur
data
local
resist
pattern
broadspectrum
antibiot
typic
need
treatment
decis
must
adapt
uncommon
sourc
suspect
fungal
infect
commonli
candida
albican
might
requir
addit
fluconazol
resist
staphylococcu
speci
might
requir
vancomycin
linezolid
diverticul
rel
common
abdomin
infect
treat
medic
outpati
basi
select
case
gener
recommend
suggest
uncompl
case
ie
patient
diverticul
first
time
without
bowel
perfor
abscess
format
patient
hydrat
oral
achiev
suffici
pain
control
discharg
instruct
obtain
outpati
treatment
followup
oral
treatment
regimen
includ
moxifloxacin
ciprofloxacin
plu
metronidazol
levofloxacin
plu
metronidazol
amoxicillinclavulan
acid
organ
typic
caus
acut
cholecyst
acut
cholang
slightli
differ
associ
intraabdomin
infect
antimicrobi
therapi
need
cover
anaerob
unless
biliaryenter
anastomosi
present
enterococc
infect
consid
patient
receiv
organ
transplant
otherwis
immunocompromis
therefor
target
organ
usual
includ
enter
gramneg
aerob
facult
bacilli
enter
gramposit
streptococci
tabl
diarrhea
common
complaint
among
ed
patient
case
pose
littl
risk
life
health
diarrheal
ill
caus
signific
discomfort
distress
diarrhea
profus
persist
patient
face
risk
dehydr
hypovolemia
patient
requir
support
care
requir
rehydr
either
oral
intraven
antimicrobi
therapi
reserv
patient
fever
hemorrhag
featur
antimicrobi
therapi
contempl
decis
obtain
target
stool
studi
made
tandem
determin
stool
studi
need
link
clinic
suspicion
inflammatori
caus
possibl
stool
sampl
examin
fecal
polymorphonuclear
leukocyt
patient
hemorrhag
shigatoxinproduc
escherichia
coli
e
coli
suspect
test
specif
organ
request
patient
communityacquir
travel
diarrhea
infect
secondari
salmonella
shigella
campylobact
e
coli
clostridium
difficil
consid
diarrhea
secondari
salmonella
shigella
treat
fluoroquinolon
adult
trimethoprimsulfamethoxazol
children
campylobact
increas
antimicrobi
resist
treat
macrolid
e
coli
suspect
patient
afebril
hemorrhag
diarrhea
given
signific
risk
hemolyt
urem
syndrom
shigatoxin
releas
diarrhea
suspect
secondari
e
coli
treat
antimicrobi
therapi
support
care
alon
recommend
c
difficil
consid
immunosuppress
patient
acut
diarrhea
recent
treat
antimicrobi
anoth
infect
initi
therapi
includ
oral
metronidazol
diarrhea
begin
recent
hospit
infect
c
difficil
consid
diarrhea
persist
day
parasit
infect
inflammatori
process
consid
idsa
conjunct
american
congress
obstetrician
gynecologist
american
urolog
societi
associ
medic
microbiolog
infecti
diseasecanada
societi
academ
emerg
medicin
updat
guidelin
treatment
uncompl
cystiti
pyelonephr
otherwis
healthi
premenopaus
women
otherwis
young
healthi
patient
uncompl
cystiti
usual
associ
fever
howev
patient
urinari
tract
symptom
fever
complain
back
pain
pyelonephr
complic
urinari
tract
infect
uti
consid
treat
cystiti
commun
hospit
antibiogram
review
vast
major
uti
commun
caus
e
coli
remaind
caus
gramneg
pathogen
includ
proteu
mirabili
k
pneumonia
gramposit
staphylococcu
saprophyticu
resist
pattern
commun
chang
frequent
follow
best
practic
recommend
one
commun
ensur
best
target
treatment
local
antibiogram
avail
idsa
guidelin
follow
box
guidelin
state
commun
resist
common
communityspecif
resist
data
realli
necessari
treatment
uti
pyelonephr
pyelonephr
consid
patient
symptom
cystiti
pair
system
symptom
fever
malais
flank
back
pain
treatment
target
specif
pathogen
therefor
cultur
gener
advis
treatment
uncompl
cystiti
empir
antibiot
chosen
base
local
resist
pattern
treat
empir
sever
option
avail
area
local
resist
less
fluoroquinolon
commonli
recommend
outpati
treatment
current
guidelin
recommend
oral
ciprofloxacin
mg
time
day
day
resist
exce
patient
intoler
hypersensit
quinolon
trimethoprimsulfamethoxazol
use
outpati
therapi
admiss
necessari
intraven
antibiot
recommend
typic
thirdgener
quinolon
catheterassoci
urinari
tract
infect
catheter
patient
risk
infect
secondari
differ
microb
compar
typic
uti
gener
patient
remain
risk
typic
organ
also
increas
risk
staphylococcu
streptococc
infect
given
instrument
urethr
tract
unfortun
typic
symptom
concern
provid
uti
may
appreci
patient
cathet
exampl
urgenc
frequenc
dysuria
present
therefor
one
must
high
index
suspicion
patient
cathet
proceed
systemat
reach
diagnosi
patient
suspect
cathet
associ
infect
unabl
simpli
remov
foley
attempt
trial
void
obtain
sampl
cathet
remov
replac
cultur
sent
new
cathet
ideal
treat
posit
urin
cultur
howev
frequent
mention
review
cultur
less
ideal
emerg
depart
urin
leukocyt
count
presenc
nitrit
urin
appear
odor
may
help
direct
clinic
suspicion
treatment
target
possibl
infect
organ
chronic
ill
popul
often
chronic
indwel
cathet
prior
cultur
data
patient
chart
review
avail
preval
resist
organ
fungal
infect
much
greater
popul
prior
data
avail
ed
use
help
direct
treatment
otherwis
discuss
treatment
focu
organ
risk
infect
patient
rel
broad
coverag
cover
gram
posit
gram
neg
anearob
organ
prostat
acut
bacteri
prostat
frequent
present
concomit
uti
hematuria
dysuria
frequenc
suprab
rectal
pain
etc
howev
extrem
import
tri
differenti
simpl
uti
associ
prostat
gener
otherwis
healthi
men
minim
risk
uti
although
acut
bacteri
prostat
uncommon
overal
preval
prostat
high
estim
approxim
male
acut
bacteri
prostat
suspect
imper
emerg
physician
start
appropri
treatment
incid
recurr
progress
chronic
bacteri
prostat
extrem
high
estim
initi
treatment
seek
optim
clearanc
offend
organ
hope
decreas
potenti
recurr
durat
treatment
often
four
week
discharg
home
patient
prompt
primari
care
follow
mention
prostat
organ
rel
limit
blood
flow
therefor
penetr
antibiot
difficult
agent
bactericid
use
common
microb
e
coli
pseudomona
proteu
klebsiella
polymicrobi
infect
therefor
antibiosi
target
gram
neg
organ
highli
recommend
agent
levofloxacin
signific
gram
neg
coverag
bactericid
renal
excret
also
withstand
low
ph
prostat
therefor
reach
desir
level
prostat
tissu
see
tabl
agent
may
consid
set
hypersent
flouroquinolon
includ
aminoglycosid
without
penicillin
like
ampicillin
thirdgener
cephalosporin
without
aminoglycosid
patient
instrument
immunocompromis
may
risk
differ
organ
cover
broadli
ensur
suffici
coverag
gramposit
organ
like
aureu
includ
address
possibl
resist
organ
presenc
fever
set
gynecolog
infect
rel
rare
howev
infect
gynecolog
tract
rel
common
given
increas
resist
neisseria
gonorrhoea
attent
antibiot
coverag
updat
import
cdc
liber
recommend
regard
treatment
pelvic
inflammatori
diseas
pid
effort
improv
control
present
pid
rang
pelvic
pain
minim
tender
fever
toxic
appear
shock
although
fever
focu
discuss
imper
stress
pelvic
pain
young
sexual
activ
femal
without
clear
caus
rais
suspicion
pid
pid
includ
infect
upper
gynecolog
tract
endometr
salping
tuboovarian
abscess
treatment
pid
mild
sever
direct
n
gonorrhoea
chlamydia
trachomati
anaerob
bacteroid
fragili
regimen
depend
sever
ill
treatment
sexual
partner
advis
tabl
pregnant
patient
suspect
pid
hospit
receiv
parenter
antibiot
manag
skin
softtissu
infect
pose
diagnost
challeng
particular
acut
infect
superimpos
chronic
chang
associ
wound
venou
stasi
might
alway
easili
detect
sever
case
manifest
system
sign
includ
fever
easier
detect
system
manifest
occur
intraven
antibiot
need
surgic
treatment
might
also
necessari
idsa
guidelin
emphas
import
key
sign
consist
sever
case
includ
pain
disproportion
examin
find
violac
bulla
cutan
hemorrhag
skin
slough
anesthesia
rapid
progress
ga
tissu
cellul
commonli
caus
gramposit
organ
streptococci
often
group
bhemolyt
streptococci
staphylococci
preval
caus
softtissu
infect
otherwis
healthi
individu
approach
distinguish
staphylococc
streptococc
cellul
base
clinic
find
aureu
often
associ
furuncl
carbuncl
abscess
cellul
associ
clear
portal
entri
diffus
erythema
found
streptococcu
speci
like
blood
cultur
routin
use
simpl
cellul
treat
empir
penicillinaseresist
penicillin
firstgener
cephalosporin
penicillinallerg
patient
treat
clindamycin
vancomycin
inpati
treatment
requir
preval
communityacquir
mrsa
increas
across
unit
state
set
preval
high
threshold
cover
low
clindamycin
trimethoprimsulfamethoxazol
tetracyclin
effect
communityacquir
mrsa
inpati
set
vancomycin
remain
antimicrobi
choic
although
option
show
promis
includ
linezolid
daptomycin
tigecyclin
necrot
infect
emerg
physician
maintain
high
index
suspicion
necrot
infect
featur
engend
concern
includ
pain
proport
appear
skin
necrosi
crepitu
ga
detect
imag
bulla
skin
slough
mark
edema
firm
subcutan
tissu
extend
beyond
erythema
cutan
anesthesia
rapid
progress
evid
sepsi
necrot
infect
develop
patient
vascular
insuffici
heighten
risk
eg
diabet
patient
venou
stasi
lymphedema
peripher
vascular
diseas
antibiot
therapi
requir
emerg
surgic
sourc
control
cornerston
therapi
infect
caus
singl
organ
eg
streptococcu
pyogen
vibrio
vulnifican
aeromona
hydrophila
mrsa
polymicrobi
infect
common
patient
penetr
trauma
concomit
reduct
blood
flow
increas
risk
ga
gangren
particularli
worrisom
polymicrobi
infect
often
caus
clostridium
speci
broadspectrum
antibiot
cover
gramposit
organ
gramneg
organ
aerob
anaerob
requir
current
treatment
recommend
mix
infect
indic
penicillin
blactamas
inhibit
combin
clindamycin
ciprofloxacin
fournier
gangren
consid
patient
perin
cellulitisnecrot
fasciiti
perian
complex
uti
histori
trauma
may
allow
entri
bacteria
genit
fascial
plane
aggress
intraven
administr
antibiot
specif
cover
pseudomona
requir
debrid
definit
treatment
choic
time
antimicrobi
therapi
challeng
acut
care
physician
resist
antimicrobi
develop
certain
pathogen
chang
emerg
physician
approach
patient
process
prioriti
determin
role
emerg
physician
steward
health
care
resourc
grow
case
organ
approach
evalu
diagnosi
treatment
help
use
antimicrobi
ration
mean
ensur
right
treatment
avail
right
peopl
right
time
right
place
